OmniAb (NASDAQ:OABI) Announces Earnings Results

OmniAb (NASDAQ:OABI) issued its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.07, FiscalAI reports. The firm had revenue of $13.41 million for the quarter, compared to analyst estimates of $4.69 million. OmniAb had a negative return on equity of 16.45% and a negative net margin of 115.12%.

Here are the key takeaways from OmniAb’s conference call:

• Q2 revenue rose to $13.4 million from $3.9 million year over year, driven primarily by partner milestone revenue; net loss narrowed to $5.9 million from $15.9 million.
• OmniAb raised and narrowed its 2026 guidance, now forecasting revenue of $32 million–$36 million, GAAP operating expenses of $84 million–$88 million, and year-end cash of $37 million–$41 million.
• The partnered pipeline continued to advance, with 425 active programs, 34 active clinical programs or approved products, four new clinical entrants in 2026, and approximately $340 million in remaining potential milestones tied to clinical-stage programs.
• The company sold two xPloration instruments during Q2, bringing the field total to four, and said the platform could generate recurring revenue from consumables, software, maintenance, and services.
• Revenue remains heavily dependent on milestone timing and was front-loaded in the first half of 2026; despite improved cash use, OmniAb expects to end the year with less cash than the $52 million held at the end of Q2.

OmniAb Trading Up 37.5%

Shares of NASDAQ OABI traded up $0.84 during midday trading on Friday, hitting $3.08. The company’s stock had a trading volume of 2,672,840 shares, compared to its average volume of 402,782. The firm has a market capitalization of $445.92 million, a price-to-earnings ratio of -8.56 and a beta of 0.45. The stock has a fifty day moving average price of $2.26 and a 200 day moving average price of $1.96. OmniAb has a one year low of $1.30 and a one year high of $3.12.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OABI. AQR Capital Management LLC bought a new stake in OmniAb during the 1st quarter valued at $25,000. Jane Street Group LLC boosted its holdings in shares of OmniAb by 26.3% in the first quarter. Jane Street Group LLC now owns 80,778 shares of the company’s stock worth $194,000 after acquiring an additional 16,823 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of OmniAb by 28.3% in the second quarter. JPMorgan Chase & Co. now owns 793,734 shares of the company’s stock worth $1,381,000 after acquiring an additional 175,297 shares during the period. Rhumbline Advisers grew its position in shares of OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after purchasing an additional 9,163 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of OmniAb by 17.0% in the second quarter. Invesco Ltd. now owns 109,613 shares of the company’s stock valued at $191,000 after purchasing an additional 15,912 shares in the last quarter. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OmniAb has a consensus rating of “Hold”.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.